公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2019 | Patients with head and neck cancer may need more intensive pain management to maintain daily functioning: a multi-center study | Cho, Shih Feng; Rau, Kun Ming; YU-YUN SHAO ; Yen, Chia Jui; Wu, Ming Fang; Chen, Jen Shi; Chang, Cheng Shyong; Yeh, Su Peng; Chiou, Tzeon Jye; Hsieh, Ruey Kuen; Lee, Ming Yang; Sung, Yung Chuan; Lee, Kuan Der; Lai, Pang Yu; Yu, Ming Sun; Hwang, Wen Li; Liu, Ta Chih | Supportive Care in Cancer | 11 | 10 | |
2018 | A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma | SHIH-HUNG YANG ; YU-YUN SHAO ; CHIA-CHI LIN ; SUNG-HSIN KUO ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 3 | 2 | |
2017 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) | Abou-Alfa G.K.; Yen C.-J.; CHIH-HUNG HSU ; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; YU-YUN SHAO ; ZHONG-ZHE LIN ; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG ; Carrasquilo J.A. | Cancer Chemotherapy and Pharmacology | 20 | 19 | |
2010 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Ying-Chun Shen ; ZHONG-ZHE LIN ; PEI-JER CHEN ; YU-YUN SHAO ; Ding Y.-H.; CHIUN HSU ; ANN-LII CHENG | Journal of Hepatology | 110 | 103 | |
2013 | A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy | YU-YUN SHAO ; PO-CHIN LIANG ; YAO-MING WU ; Huang C.-C.; KAI-WEN HUANG ; CHIA-HSIEN CHENG ; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; ZHONG-ZHE LIN | Liver International | 15 | 15 | |
2010 | Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma | YU-YUN SHAO ; RUEY-LONG HONG | Oral Oncology | 6 | 7 | |
2019 | Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma | YU-YUN SHAO ; Yong-Shi Li; Hung-Wei Hsu; Hang Lin; Han-Yu Wang; Rita Robin Wo; ANN-LII CHENG ; CHIH-HUNG HSU | Cancers | 14 | 14 | |
2021 | Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma | Hung Y.-P.; YU-YUN SHAO ; Lee J.-M.; CHIUN HSU ; CHIH-HUNG HSU ; Yang M.-H.; Chao Y. | Journal of the Chinese Medical Association | 10 | 9 | |
2010 | Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin | YU-YUN SHAO ; KUAN-TING KUO ; Hu F.-C.; YEN-SHEN LU ; CHIUN-SHENG HUANG ; JAU-YU LIAU ; Lee W.-C.; CHIUN HSU ; WEN-HUNG KUO ; KING-JEN CHANG ; CHING-HUNG LIN ; ANN-LII CHENG | Japanese Journal of Clinical Oncology | 28 | 24 | |
2015 | Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? | YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG | World Journal of Gastroenterology | 36 | 38 | |
2017 | Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study | LI-CHUN LU ; PEI-JER CHEN ; Yeh Y.-C.; CHIH-HUNG HSU ; Chen H.-M.; Lai M.-S.; YU-YUN SHAO ; ANN-LII CHENG | Anticancer Research | 15 | 16 | |
2016 | Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study | KUO-HSING CHEN ; YU-YUN SHAO ; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN ; Lai M.-S.; ANN-LII CHENG ; KUN-HUEI YEH | BMC Cancer | 39 | 39 | |
2022 | Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment | Chen, Ching-Tso; Feng, Yin-Hsun; Yen, Chia-Jui; Chen, San-Chi; Lin, Yun-Tzu; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | Hepatology international | 14 | 14 | |
2012 | Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems | YU-YUN SHAO ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | British Journal of Cancer | 26 | 26 | |
2014 | Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy | YU-YUN SHAO ; CHIH-HORNG WU ; LI-CHUN LU ; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; CHIH-HUNG HSU ; ANN-LII CHENG | Journal of Hepatology | 45 | 48 | |
2015 | The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia | HUNG-YANG KUO ; ZHONG-ZHE LIN ; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO ; CHIUN HSU ; WEN-FANG CHENG ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Oncologist | 10 | 10 | |
2013 | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size | ZHONG-ZHE LIN ; Shau W.-Y.; CHIUN HSU ; YU-YUN SHAO ; Yeh Y.-C.; Kuo R.N.-C.; CHIH-HUNG HSU ; CHIH-HSIN YANG ; ANN-LII CHENG ; Lai M.-S. | PLoS ONE | 26 | 24 | |
2021 | Reply to letter to the editor: Low skeletal muscle mass are predictive factors of survival for advanced hepatocellular carcinoma | CHIH-HORNG WU ; YU-YUN SHAO ; TIFFANY TING-FANG SHIH | Journal of the Formosan Medical Association = Taiwan yi zhi | 0 | 0 | |
2021 | Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma | Chen, Ching-Tso; TSUNG-HAO LIU ; YU-YUN SHAO ; KAO-LANG LIU ; PO-CHIN LIANG ; ZHONG-ZHE LIN | International journal of molecular sciences | 16 | 8 | |
2017 | Right or left? Side selection for a totally implantable vascular access device: A randomised observational study | WEN-YING LIN ; CHIH-PENG LIN ; CHIH-HUNG HSU ; Lee, Ying Hui; Lin, Yi Ting; Hsu, Meng Chi; YU-YUN SHAO | British Journal of Cancer | 13 | 10 | |